Semaxinib

Overview

Semaxinib is a quinolone derivative with potential antineoplastic activity. Semaxinib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Source summary: Semaxinib is a potent tyrosine kinase inhibitor used in the study of signaling pathways and cancer research. Enhance your research; inquire now for availability!

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | VEGFR

Product Information

• Catalog No.: B0084-352931
• CAS No.: 204005-46-9
• Molecular Formula: C15H14N2O
• Molecular Weight: 238.28
• Purity: 98%

Source

Original product source